Insider Selling: Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP Sells 33,732 Shares of Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) EVP David Sponsel sold 33,732 shares of Alphatec stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $10.83, for a total value of $365,317.56. Following the completion of the sale, the executive vice president now directly owns 668,977 shares of the company's stock, valued at approximately $7,245,020.91. This represents a 4.80 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

David Sponsel also recently made the following trade(s):

• On Monday, February 24th, David Sponsel sold 12,946 shares of Alphatec stock. The shares were sold at an average price of $10.73, for a total value of $138,910.58.
• On Monday, February 3rd, David Sponsel sold 36,256 shares of Alphatec stock. The stock was sold at an average price of $11.42, for a total transaction of $414,043.52.
• On Monday, January 13th, David Sponsel sold 58,283 shares of Alphatec stock. The stock was sold at an average price of $10.71, for a total transaction of $624,210.93.
• On Friday, January 10th, David Sponsel sold 238 shares of Alphatec stock. The shares were sold at an average price of $10.00, for a total transaction of $2,380.00.

Alphatec Stock Down 3.0 %

Shares of ATEC stock traded down $0.29 during trading on Thursday, hitting $9.27. 1,705,990 shares of the company were exchanged, compared to its average volume of 1,980,945. Alphatec Holdings, Inc. has a twelve month low of $4.88 and a twelve month high of $14.88. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32. The firm has a market capitalization of $1.34 billion, a price-to-earnings ratio of -7.24 and a beta of 1.39. The business's 50-day simple moving average is $10.94 and its 200 day simple moving average is $8.70.

Remove Ads

Alphatec (NASDAQ:ATEC - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.04). The firm had revenue of $176.79 million for the quarter, compared to analyst estimates of $172.74 million. Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. As a group, analysts forecast that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ATEC has been the topic of several research reports. Barclays raised their price objective on Alphatec from $20.00 to $21.00 and gave the company an "overweight" rating in a research report on Wednesday, January 22nd. HC Wainwright reaffirmed a "buy" rating and set a $20.00 price target on shares of Alphatec in a report on Tuesday, January 14th. Piper Sandler boosted their price objective on shares of Alphatec from $12.00 to $13.00 and gave the stock an "overweight" rating in a report on Thursday, February 27th. Needham & Company LLC reiterated a "buy" rating and issued a $16.00 price target on shares of Alphatec in a research note on Thursday, February 27th. Finally, StockNews.com upgraded Alphatec from a "sell" rating to a "hold" rating in a research note on Friday, February 28th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $17.67.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ATEC. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its holdings in shares of Alphatec by 11.3% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,928,094 shares of the medical technology company's stock worth $16,280,000 after acquiring an additional 297,850 shares during the period. Barclays PLC grew its holdings in shares of Alphatec by 362.3% in the 3rd quarter. Barclays PLC now owns 170,546 shares of the medical technology company's stock worth $948,000 after purchasing an additional 133,653 shares during the last quarter. Franklin Resources Inc. increased its position in shares of Alphatec by 299.3% during the 3rd quarter. Franklin Resources Inc. now owns 64,450 shares of the medical technology company's stock worth $343,000 after purchasing an additional 48,308 shares in the last quarter. Royce & Associates LP lifted its holdings in Alphatec by 15.9% during the 3rd quarter. Royce & Associates LP now owns 1,212,286 shares of the medical technology company's stock valued at $6,740,000 after purchasing an additional 165,954 shares during the last quarter. Finally, State Street Corp grew its stake in Alphatec by 10.1% during the third quarter. State Street Corp now owns 3,138,960 shares of the medical technology company's stock worth $17,453,000 after buying an additional 287,350 shares during the last quarter. Institutional investors own 66.35% of the company's stock.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.